Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CD

WKN: A41UNJ | ISIN: US1897632048 | Ticker: C970
NASDAQ
19.11.26 | 21:58
0,163 US-Dollar
-1,22 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CO-DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
CO-DIAGNOSTICS INC 5-Tage-Chart

Aktuelle News zur CO-DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CO-DIAGNOSTICS Aktie jetzt für 0€ handeln
DoCo-Diagnostics kündigt Aktienzusammenlegung im Verhältnis 1 zu 25 an1
DoCo-Diagnostics announces 1-for-25 reverse stock split5
DoCo-Diagnostics, Inc. - 8-K, Current Report-
DiCo-Diagnostics receives test order from Peru amid dengue rise2
11.11.Co-Diagnostics GAAP EPS of -$1.01 beats by $0.24, revenue of $0.28M beats by $0.11M2
11.11.Co-Diagnostics outlines India TB submission with ~97.3% sensitivity and ~96% specificity as $6.2M Q3 operating expenses decline 12%1
10.11.Co-Diagnostics, Inc. - 10-Q, Quarterly Report-
10.11.Co-Diagnostics, Inc. (CODX) Q3 Sales Increase3
10.11.Co-Diagnostics Reports Third Quarter 2026 Financial Results244Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and...
► Artikel lesen
10.11.Co-Diagnostics, Inc. - 8-K, Current Report-
27.10.Co-Diagnostics Moves Closer to Commercial Tuberculosis Test Launch in India6
27.10.Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India488CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026Study Demonstrated 97.3% Sensitivity and 96.0% SpecificityConsistent Performance Across Three Test BatchesIntegrated Mobile...
► Artikel lesen
20.10.Joint Venture von Co-Diagnostics zu saudi-arabischem Fertigungsforum eingeladen1
20.10.Co-Diagnostics joint venture invited to Saudi manufacturing forum1
13.10.Co-Diagnostics, Inc. - 8-K, Current Report26
25.09.Co-Diagnostics, Inc. - 8-K, Current Report3
15.09.Co-Diagnostics, Inc. - 8-K, Current Report2
04.09.Co-Diagnostics, Inc. - 8-K, Current Report4
14.08.Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M7
13.08.Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript7
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1